XRAY insider: Daniel Scavilla receives 1.10M options at $12.96 and disposes 17,475 shares

Rhea-AI Filing Summary

DENTSPLY SIRONA insider Daniel T. Scavilla, who serves as President, CEO and director, reported transactions dated 08/08/2025. The filing shows a disposition of 17,475.049 shares of common stock and the acquisition of 1,102,600 stock options with an exercise price of $12.96. The options are exercisable beginning 08/08/2026 and expire 08/08/2035. The grant vests in three equal annual installments, ending 08/08/2028, and is recorded with a price of $0. Ownership of the reported derivative and the disposal are shown as direct. No additional financial metrics or compensatory values are provided in the form.

Positive

• Grant of 1,102,600 stock options to the CEO, which can align executive incentives with shareholder value over time
• Clear vesting schedule: options vest in annual one-third increments ending 08/08/2028, providing transparency on retention terms

Negative

• Disposition of 17,475.049 shares by the reporting person, reducing direct shareholdings reported on this form

Insights

Financial Analyst

Routine combination of a stock sale and a large option grant by the CEO; aligns compensation but appears standard.

The Form 4 documents a disposition of 17,475.049 common shares and the grant/acquisition of 1,102,600 stock options at an exercise price of $12.96. Options become exercisable on 08/08/2026 and expire on 08/08/2035. The options vest in three equal annual tranches through 08/08/2028, which is consistent with multi-year retention and performance-aligned compensation structures. The filing does not include additional compensation values, proceeds from the disposition, or contextual company financials, so valuation or immediate market impact cannot be assessed from this form alone.

Corporate Governance Expert

Insider disclosure shows standard executive grant with time-based vesting and a concurrent small share disposition.

The reporting person is identified as President, CEO & Member of the Board. The grant has a defined vesting schedule: annual one-third vesting over three years ending 08/08/2028, exercisable from 08/08/2026 through 08/08/2035, and is held directly. The form records a disposal of 17,475.049 shares. From a governance perspective, the disclosure is complete for the transactions shown, but the form does not state the rationale for the disposal or whether the option grant is tied to specific performance targets beyond the time-based vesting noted.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scavilla Daniel T

(Last) (First) (Middle)

C/O DENTSPLY SIRONA INC

13320-B BALLANTYNE CORPORATE PLACE

(Street)

CHARLOTTE NC 28277

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DENTSPLY SIRONA Inc. [ XRAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, CEO & Member of BOD

3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								17,475.049	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.96	08/08/2025		A		1,102,600		08/08/2026(1)	08/08/2035	Common Stock	1,102,600	$0	1,102,600	D

Explanation of Responses:

1. Stock options vest in annual one-third (1/3) increments over a three (3) year period ending August 8, 2028.

	/s/ Jessica Causey, Attorney-in-Fact for Daniel T. Scavilla	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did DENTSPLY SIRONA (XRAY) report on this Form 4?

The form reports a disposition of 17,475.049 common shares and the acquisition/grant of 1,102,600 stock options dated 08/08/2025.

How many stock options were granted to Daniel T. Scavilla and at what exercise price?

He was reported to have acquired 1,102,600 stock options with an exercise/conversion price of $12.96.

When do the options become exercisable and when do they expire?

The options are exercisable beginning 08/08/2026 and expire on 08/08/2035.

What is the vesting schedule for the granted options?

The options vest in annual one-third (1/3) increments over three years, ending on 08/08/2028.

What is Daniel T. Scavilla's role at DENTSPLY SIRONA as shown on the form?

He is identified as President, CEO & Member of the Board and is reported as a Director and officer.